Clearly, further in‐depth prospective analysis of PRG‐1+/mut carriers and case–control studies in patient cohorts with psychiatric diseases is needed to ultimately design novel treatment approaches based on targeted intervention to synaptic lipid signaling. The gene discussed is PLPPR4; the disease is psychiatric disorder.